Symbols

EPIX(Delisted)

ESSA Pharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 0

Bearish signal 1

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About EPIX

Essa Pharma Inc.

A clinical-stage pharmaceutical company that developing novel therapies for the treatment of prostate cancer

Industry

Established Date

01/06/2009

Listing Date

07/09/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

09-30

Website

www.essapharma.com

Security Type

Common stock

Office address

Suite 720, 999 West Broadway, Vancouver, BC V5Z 1K5

Business

Introduction

ESSA Pharma Inc., was incorporated under the laws of British Columbia on January 6, 2009. The Company is a development-stage pharmaceutical company focused on the development of small molecule drugs for the treatment of castrated prostate cancer (" CRPC "). The company is developing drugs that selectively block the amino terminal domain (" NTD ") of the androgen receptor (" AR "), which can potentially overcome the known AR-dependent mechanism of CRPC, so that patients with CRPC do not deteriorate and improve survival.

Company Financials

EPS

EPIX has released its 2025 Q3 earnings. EPS was reported at -0.09, versus the expected -0.17566974088704, beating expectations. The chart below visualizes how EPIX has performed over recent quarters, highlighting trends in earnings surprises.